The University of Colorado discovered, in the Journal of Chromatography 2003, that matcha green tea (a powdered version of green tea - as sold by Vitalife Teas) contains 137x the antioxidant EGCG compared to traditional steeped-leaf green teas - making it a great way to detoxify and rejuvenate this January.
Rotherham, South Yorkshire (PRWEB UK) 2 January 2013
'Matcha green tea has been drank for centuries by Buddhist monks, but studies are now suggesting that matcha has more potent antioxidant effects compared to traditional green tea' explain Vitalife Teas.
EGCG (Epigallocatechin Gallate) is a type of catechin, found in green tea and cocoa, that according to the University of Alabama in their study 'Epigenetics of Dietary EGCG, 2008', has been found to be anti-carcinogenic - helping to rid the body of damaging free radicals and toxins.
The fact that matcha green tea contains 137x the EGCG content of traditional steeped-leaf green tea means that matcha could become a household favourite this January as people look for ways to recover from the overindulgence and toxins consumed over the Festive period.
Gavin Edley, Director of South Yorkshire based Vitalife Teas, explained 'Matcha is becoming more popular every year as people discover its benefits to health - modern science is starting to prove why the Buddhist monks used matcha green tea to help them endure lengthy meditation sessions all those years ago'.
It is basically a powdered green tea, ground on traditional stone mills, after being grown under bamboo sheets to limit its exposure to sunlight and force the plant to fill with chlorophyll and work harder to photosynthesise.
This chlorophyll has reported health benefits in itself, and gives matcha green tea its distinctive, vivid green colour when mixed with warm water for consumption.
Vitalife have become one of the UK's leading brands of matcha green tea, and offer a range of different grades and flavours of matcha at http://www.vitalifeteas.com.
Matcha may just become even more of a January detox favourite with this research in-mind.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10281956.htm
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.